Clinical trial
IPX056 in Subjects With Established Spasticity Resulting From Multiple Sclerosis
NCT00488839 · Impax Laboratories, LLC, Industry · Completed
Key facts
| NCT number | NCT00488839 |
|---|---|
| Title | IPX056 in Subjects With Established Spasticity Resulting From Multiple Sclerosis |
| Official title | A Double-Blind, Randomized, Placebo- and Active Comparator- Controlled, Parallel Group, Multinational Study to Evaluate the PK and PD of IPX056 in Subjects With Established Spasticity Resulting From Multiple Sclerosis |
| Lead sponsor | Impax Laboratories, LLC, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Multiple Sclerosis |
| Intervention type | Drug |
| Interventions | IPX056 20 mg, IPX056 40 mg, Encapsulated Baclofen 20 mg, Placebo Baclofen Tablet, IPX056 10 mg, IPX056 30 mg, IPX056 35 mg, Placebo IPX056 20 mg, Placebo IPX056 40 mg |
| Enrollment | 173 |
| Start date | Jun 1, 2007 |
| Primary completion | May 1, 2008 |
| Completion | May 1, 2008 |
| First posted | Jun 20, 2007 |
| Last update posted | Nov 6, 2019 |
| Countries | Canada, Estonia, Latvia, Ukraine, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: